JP7084057B2 - 新規抗ｐａｄ２抗体 - Google Patents

新規抗ｐａｄ２抗体 Download PDF

Info

Publication number
JP7084057B2
JP7084057B2 JP2020525771A JP2020525771A JP7084057B2 JP 7084057 B2 JP7084057 B2 JP 7084057B2 JP 2020525771 A JP2020525771 A JP 2020525771A JP 2020525771 A JP2020525771 A JP 2020525771A JP 7084057 B2 JP7084057 B2 JP 7084057B2
Authority
JP
Japan
Prior art keywords
pad2
antibody
present
amino acid
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020525771A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019244934A1 (ja
Inventor
憲二 斉藤
知子 坂田
峻哲 川野邊
啓太 古賀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma Foods International Co Ltd
Original Assignee
Pharma Foods International Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Foods International Co Ltd filed Critical Pharma Foods International Co Ltd
Publication of JPWO2019244934A1 publication Critical patent/JPWO2019244934A1/ja
Priority to JP2022085941A priority Critical patent/JP7411264B2/ja
Application granted granted Critical
Publication of JP7084057B2 publication Critical patent/JP7084057B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03015—Protein-arginine deiminase (3.5.3.15)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2020525771A 2018-06-20 2019-06-19 新規抗ｐａｄ２抗体 Active JP7084057B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022085941A JP7411264B2 (ja) 2018-06-20 2022-05-26 新規抗ｐａｄ２抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018117142 2018-06-20
JP2018117142 2018-06-20
PCT/JP2019/024310 WO2019244934A1 (ja) 2018-06-20 2019-06-19 新規抗ｐａｄ２抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022085941A Division JP7411264B2 (ja) 2018-06-20 2022-05-26 新規抗ｐａｄ２抗体

Publications (2)

Publication Number Publication Date
JPWO2019244934A1 JPWO2019244934A1 (ja) 2021-06-24
JP7084057B2 true JP7084057B2 (ja) 2022-06-14

Family

ID=68984058

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020525771A Active JP7084057B2 (ja) 2018-06-20 2019-06-19 新規抗ｐａｄ２抗体
JP2022085941A Active JP7411264B2 (ja) 2018-06-20 2022-05-26 新規抗ｐａｄ２抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022085941A Active JP7411264B2 (ja) 2018-06-20 2022-05-26 新規抗ｐａｄ２抗体

Country Status (6)

Country Link
US (1) US12559570B2 (https=)
EP (1) EP3816289A4 (https=)
JP (2) JP7084057B2 (https=)
CN (1) CN112262213A (https=)
CA (1) CA3102360A1 (https=)
WO (1) WO2019244934A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4501354A4 (en) * 2022-03-31 2026-03-25 Pharma Foods Int Co Ltd COMPOSITION AND METHOD OF INHIBITING FIBROSIS
CN118001407B (zh) * 2024-04-02 2024-06-21 北京大学人民医院 Pad2在制备治疗缺血缺氧性恶性心律失常药物中的应用
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators
CN121270710B (zh) * 2025-04-14 2026-03-31 北京光辉天成生物科技有限公司 一种高亲和力padi2抗体及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014086365A1 (en) 2012-12-03 2014-06-12 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
WO2016155745A1 (en) 2015-03-27 2016-10-06 Rigshospitalet Cross-reactive anti-pad antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
WO2005097421A2 (en) * 2004-04-01 2005-10-20 Sequenom, Inc. Methods for identifying risk of osteoarthritis and treatments thereof
WO2007095250A2 (en) * 2006-02-13 2007-08-23 The Cleveland Clinic Foundation Compositions and methods for inhibiting optic nerve damage
CN101293916A (zh) 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
CN101293924A (zh) 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
NO2294086T3 (https=) * 2008-06-04 2018-02-10
US8975033B2 (en) 2012-11-05 2015-03-10 The Johns Hopkins University Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
CN104360070B (zh) 2014-11-28 2017-02-22 山东新创生物科技有限公司 肽基精氨酸脱亚胺酶2在制备肿瘤临床血液诊断试剂中的应用
EP4161963A4 (en) 2020-06-03 2024-07-03 Georg F. Weber ISOLATED ANTIBODIES AND FRAGMENTS THEREOF WITH SPECIFICITY TO OSTEOPONTIN-C

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014086365A1 (en) 2012-12-03 2014-06-12 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
WO2016155745A1 (en) 2015-03-27 2016-10-06 Rigshospitalet Cross-reactive anti-pad antibodies

Also Published As

Publication number Publication date
WO2019244934A1 (ja) 2019-12-26
CN112262213A (zh) 2021-01-22
CA3102360A1 (en) 2019-12-26
US20210246225A1 (en) 2021-08-12
EP3816289A4 (en) 2022-03-02
JP7411264B2 (ja) 2024-01-11
JPWO2019244934A1 (ja) 2021-06-24
JP2022119899A (ja) 2022-08-17
US12559570B2 (en) 2026-02-24
EP3816289A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
US20260116998A1 (en) Novel anti-pad4 antibody
US20240141053A1 (en) Antibodies against tl1a and uses thereof
CN110769851B (zh) 兽用抗il31抗体
JP7411264B2 (ja) 新規抗ｐａｄ２抗体
ES2377579T3 (es) Anticuerpos de alta afinidad contra el receptor de IL-6 humano
JP6400480B2 (ja) ペプチドグリカン認識タンパク質１に結合する抗体
JP7624185B2 (ja) 新規抗ｐａｄ４抗体
TWI635097B (zh) 新穎抗人類ｔｓｌｐ受體抗體
CN113164593A (zh) 兽用抗il4受体抗体
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
US11548938B2 (en) DbpA antibodies and uses thereof
JP7459075B2 (ja) スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体
CN107522783B (zh) 一种抗白介素17a的抗体、其制备方法和应用
JP2019537617A (ja) インターロイキン１７ａを標的とする抗体、その製造方法及び応用
CN119301153A (zh) 结合il-17a和il-17f的抗体分子及其应用
TW201139459A (en) Osteopontin-specific monoclonal antibodies
HK1243095A1 (en) An anti-il-17a antibody, the preparation method and application thereof
HK1243095A (en) An anti-il-17a antibody, the preparation method and application thereof
BR122024020794A2 (pt) Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220526

R150 Certificate of patent or registration of utility model

Ref document number: 7084057

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250